Peptide (e.g., Protein, Etc.) Containing Doai Patents (Class 514/1.1)
  • Patent number: 10286000
    Abstract: The invention is directed to the use of Retinoid X Receptor-gamma (RXR-gamma) agonists and Retinoid X Receptor-alpha (RXR-alpha) antagonists in treatment of cancer.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: May 14, 2019
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Wai-Hang Leung, Wing Leung
  • Patent number: 10278912
    Abstract: Provided herein are microalgal polysaccharide compositions and. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: May 7, 2019
    Assignee: Algenist Holdings, Inc.
    Inventors: Anna Coragliotti, Scott Franklin, Anthony G. Day, Stephen M. Decker
  • Patent number: 10271570
    Abstract: A composition for diet supplementation to improve gut microflora is disclosed. The composition includes a prebiotic source and source of nucleotides, such as an extract of yeast. Also disclosed are methods of diet supplementation that include administering compositions of the invention to an individual.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: April 30, 2019
    Assignee: NU SCIENCE LABORATORIES, INC.
    Inventor: Mark G. Connell
  • Patent number: 10272069
    Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 30, 2019
    Assignee: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO
    Inventors: Dean Burkin, Ryan Wuebbles
  • Patent number: 10272158
    Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms. The present invention provides, in various aspects, compounds and methods for the treatment of infections, such as biofilm infections or chronic biofilm infections. The chronic biofilm infection may occur in wounds, implanted devices, immunocompromised patients, people with cystic fibrosis, eye infections, etc.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: April 30, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hugh Smyth, Ju Du
  • Patent number: 10272131
    Abstract: A method of stabilizing linaclotide in a solid dosage form, said method comprising a) preparing a composition of linaclotide, acesulfame and pharmaceutically acceptable excipients and b) converting the composition into a solid dosage form.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: April 30, 2019
    Assignee: Sun Pharmaceutical Industries Ltd.
    Inventors: Rajamannar Thennati, Shirish Kulkarni, Sanjay Poptani, Vimal Kaneria, T. Nathamani
  • Patent number: 10265371
    Abstract: Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+ cells are provided as well.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: April 23, 2019
    Assignees: UNIVERSITAT AUTONOMA DE BARCELONA, INSTITUT RECERCA HOSPITAL DE LA SANTA CREU I SANT PAU, CENTRO DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA (CIBER BBN)
    Inventors: Antonio Pedro Villaverde Corrales, Esther Vazquez Gomez, Maria Virtudes Cespedes Navarro, Isolda Casanova Rigat, Neus Ferrer Miralles, Ramon Mangues Bafalluy, Ugutz Unzueta Elorza
  • Patent number: 10266896
    Abstract: Compositions and methods for the detection and treatment of T1D are provided.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: April 23, 2019
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Struan F. A. Grant, Jonathan P. Bradfield, Constantin Polychronakos
  • Patent number: 10253333
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: April 9, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
  • Patent number: 10238742
    Abstract: Cancer cells with defects in DNA repair are highly susceptible to DNA-damaging agents, but delivery of therapeutic agents into cell nuclei can be challenging. A sub-set of autoantibodies having nucleolytic activity are capable of nuclear penetration. These antibodies can be used as therapeutic agents targeted towards DNA repair-deficient malignancies.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: March 26, 2019
    Assignees: Yale University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: James E. Hansen, Richard H. Weisbart, Philip W. Noble
  • Patent number: 10239937
    Abstract: Methods for treating subjects having complement-mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and other hemolytic anemias, the method comprising administering an effective amount of a composition that inhibits the activity of the complement alternative pathway.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: March 26, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: V. Michael Holers, Antonio M. Risitano
  • Patent number: 10232197
    Abstract: An antimicrobial composition compatible with anionic compounds is prepared by a process of contacting a cationic peptide-based antimicrobial extract with an ion exchange resin.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: March 19, 2019
    Assignee: Active Micro Technologies, LLC
    Inventors: Durant Scholz, Erica Segura
  • Patent number: 10234460
    Abstract: An object of the present invention is to provide a peptide excellent in resistance against metabolism, having a stable structure in vivo, and capable of penetrating a cell membrane and reaching in cells. The present invention provides a macrocyclic peptide having a macrocyclic structure comprised of four or more amino acids. At least two amino acids not adjacent to each other have a hydrophobic side chain and the hydrophobic side chains interact with each other inside the ring of the macrocyclic peptide in a hydrophilic environment.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: March 19, 2019
    Assignee: The University of Tokyo
    Inventor: Hiroaki Suga
  • Patent number: 10221456
    Abstract: This application is directed to the use of biomarkers for predicting the sensitivity to treatment with an FGF-18 compound of a patient having a cartilage disorder, such as osteoarthritis, cartilage injury, fractures affecting joint cartilage or surgical procedures with impact on joint cartilage (e.g., microfracture), in order to reduce the risk of adverse events and increase the overall benefit after therapy.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: March 5, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph Hubertus Ladel, Alix Anne Simone Berton, Armand Valsesia, Pierre Jacques Farmer
  • Patent number: 10222384
    Abstract: We disclose a method of detecting the metabolic health of a mammal, including a human, by determining whether a given animal is normal, pre-diabetic or diabetic through the determination of the levels of Wnt4 and Wnt3a proteins in the blood serum.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: March 5, 2019
    Assignee: INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO, POLSKIEJ AKADEMII NAUK
    Inventors: Agnieszka Dobrzyn, Kamil Kozinski, Pawel Dobrzyn, Tomasz Bednarski
  • Patent number: 10220069
    Abstract: The present invention relates to the field of diabetes mellitus. More specifically, the present invention provides compositions and methods useful for treating diabetes. In another embodiment, a method for treating type 2 diabetes mellitus or pre-diabetes in a patient comprises administering to the patient an effective amount of inhibitor of kisspeptin 1 and/or proteolytic derivatives thereof.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: March 5, 2019
    Assignee: The Johns Hopkins University
    Inventors: Mehboob Hussain, Prosenjit Mondal, Woo-Jin Song
  • Patent number: 10220004
    Abstract: A method for controlled delivery of a substance into a body includes administering a plurality of containment vessels into the body, in which each of the plurality of containment vessels includes a quantity of the substance loaded therein prior to the administering; and providing a time-varying magnetic field such that the plurality of containment vessels are exposed thereto to cause a release of at least a portion of the substance from the plurality of containment vessels. Each of the plurality of containment vessels has an average outer diameter less than about 1 ?m.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: March 5, 2019
    Assignee: The Regents of the University of California
    Inventors: Jeffrey I. Zink, Courtney R. Thomas, Monty Liong, Sarah Ann Henscheid, Jinwoo Cheon, Jae-Hyun Lee, Daniel P. Ferris
  • Patent number: 10221239
    Abstract: The present invention relates to methods for treating ischemic stroke including extension of the therapeutic time window for reperfusion. More particularly, the invention relates to a method of treating stroke in a subject by inhibiting the transient receptor potential melastatin 4 (TRPM4) channel. The present invention also provides uses of TRPM4 inhibitors, TRPM4 antibodies and kits for use in the methods of the invention.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: March 5, 2019
    Assignee: SINGAPORE HEALTH SERVICES PTE LTD
    Inventors: Ping Liao, Kok Poh Loh
  • Patent number: 10208103
    Abstract: Molecules and compositions are described for use in the treatment and prevention of pro-inflammatory conditions. HDL-related molecules, including ApoA-I, bovine HDL and HDL mimetics, in particular, are demonstrated to prevent UV-induced cell death and oxidative stress in skin cells and to inhibit tumor growth and development in a variety of cancers. HDL-related molecules can be used as an oral supplement and in other compositions to prevent or treat pro-inflammatory skin conditions and systemic proinflammatory conditions, including Alzheimer's disease and various cancers.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: February 19, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Robin Farias-Eisner, Srinivasa T. Reddy
  • Patent number: 10201585
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof. The present technology relates to the treatment or prevention of atherosclerosis in mammals through the administration of a therapeutically effective amount of aromatic cationic peptides and, in some embodiments, a second active agent.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: February 12, 2019
    Assignee: Stealth Biotherapeutics Corp
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey
  • Patent number: 10202433
    Abstract: The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: February 12, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Nantes, Centre National de la Recherche Scientifique (CNRS), Universite D'Angers
    Inventors: Yannick Jacques, Erwan Mortier, Agnes Quemener, Ariane Plet
  • Patent number: 10195166
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hepatitis C virus (HCV) infectious disease. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating HCV infectious disease or an antiviral composition for HCV, containing at least one selected from the group consisting of: GRIM19 protein or a fragment thereof; and a gene encoding the protein or a fragment of the protein.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: February 5, 2019
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Seung Kew Yoon, Jung Hee Kim, Won Hee Hur, Mi La Cho, Jung Eun Choi, Eun Byul Lee
  • Patent number: 10196425
    Abstract: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 5, 2019
    Assignee: RHYTHM PHARMACEUTICALS, INC.
    Inventors: Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart Henderson
  • Patent number: 10191041
    Abstract: Disclosed herein are systems and methods for detecting Chemical Species, Biomolecules and Biotargets (Analytes) using receptor functionalized metal nanoparticles and Dynamic Light Scattering.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: January 29, 2019
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Qun Huo, Xiong Liu, Qiu Dai
  • Patent number: 10183029
    Abstract: The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: January 22, 2019
    Assignee: Ferring B.V.
    Inventor: Joan-Carles Arce
  • Patent number: 10183020
    Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methyl-amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: January 22, 2019
    Assignee: AstraZeneca AB
    Inventors: Cindy Finnie, Steven Anthony Raw, David Wilson
  • Patent number: 10179194
    Abstract: The present invention relates to the use of peptides, peptoids and/or peptidomimetics capable of self-assembling and forming a (nanofibrous) hydrogel in biofabrication. The present invention further relates to methods for preparing hydrogels and to methods for preparing continuous fibres and to methods for obtaining multi-cellular constructs with defined, precise geometrics. The present invention further relates to various uses of such hydrogels for obtaining mini-hydrogel arrays and 3D organoid structures or 3D macromolecular biological constructs.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: January 15, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Charlotte Hauser, Yihua Loo
  • Patent number: 10172911
    Abstract: Disclosed are methods of modulating erythropoiesis with arginine vasopressin receptor 1B (AVPR1B) molecules, such as AVPR1B agonists or antagonists. In one example, a method of stimulating erythropoiesis is disclosed including administering an effective amount of an AVPR1B stimulatory molecule to a subject in need thereof, thereby stimulating erythropoiesis. Also disclosed is a method of stimulating hematopoetic stem cell (HSC) proliferation which includes administering an effective amount of an AVPR1B stimulatory molecule to a subject in need thereof, thereby stimulating HSC proliferation. A method of inhibiting HSC proliferation including administering an effective amount of an AVPR1B inhibitory molecule to a subject in need thereof, thereby inhibiting HSC proliferation is provided.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: January 8, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eva M. Mezey, Balazs Mayer, Krisztian Nemeth, Miklos Krepuska
  • Patent number: 10174082
    Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogs and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogs and derivatives thereof as medicaments.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: January 8, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Lauge Schaeffer, Kirsten Dahl, Christian Poulsen, Kirsten Raun
  • Patent number: 10155049
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: December 18, 2018
    Assignee: Altimmune UK, LTD
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand V. Georges, Philip J. Sizer
  • Patent number: 10138288
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: November 27, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10138282
    Abstract: This disclosure is related to the peptide antagonist of LL-37, an antimicrobial peptide that has multiple functions in both innate and adaptive immune response. Specifically, the identified peptide antagonists of LL-37 provide inhibition to detrimental autoimmune inflammatory response, whereas at the same time retain LL-37's antibacterial activity.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: November 27, 2018
    Assignee: Indiana University Research and Technology Corporation
    Inventors: C. Cheng Kao, Divyendu Singh, Lani Rose San Mateo
  • Patent number: 10130599
    Abstract: A mineral-vitamin complex for osteoporosis includes at least 92 mass % of the mineral-vitamin complex of amino acids and Krebs cycle acids and/or Krebs cycle acid salts, wherein the amino acids include glycine of between 1% and 80% of the mineral-vitamin complex, and wherein the Krebs cycle acids and/or Krebs cycle acid salts are up to 5 mass % of the mineral-vitamin complex; and valine, leucine and isoleucine such that a mass ratio of glycine to a sum of valine+leucine+isoleucine is in a range of 10-1000. Optionally, the valine, leucine and isoleucine are derived from dry milk, any stable dry product derived from milk and/or a mix thereof. Optionally, the following compounds are used as a source of Krebs cycle acid salts: Y-Me-Y.nH2O, where Me—divalent metal, from Ca, Mg, Zn group, Y—anion of an acid participating in Krebs cycle, and n=0-12.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: November 20, 2018
    Inventors: Mikhail Lvovich Uchitel, Roman Anatolievich Trunin, Evgenij Iljich Maevskij
  • Patent number: 10130682
    Abstract: A method of treating or preventing gonadal or uterine toxicity induced by an agent in a subject is provided. Accordingly there is provided a method comprising administering to a subject a therapeutically effective amount of pigment epithelium-derived factor (PEDF), thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is, a method comprising determining gonadal function in a subject; and administering to the subject a therapeutically effective amount of PEDF, thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is a PEDF for use in the treatment or prevention of gonadal toxicity induced by an agent in a subject. Also provided are cell culture, a medium, a kit and method for improving oocyte quality ex-vivo.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 20, 2018
    Assignees: Ramot at Tel-Aviv University Ltd., Mor Research Applications Ltd.
    Inventors: Ruth Shalgi, Dana Chuderland, Hadas Bar-Joseph, Keren Goldberg, Irit Ben-Aharon, Salomon M. Stemmer
  • Patent number: 10117915
    Abstract: Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: November 6, 2018
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Donald Bellgrau, Beth Tamburini
  • Patent number: 10117907
    Abstract: A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PAC1 receptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including ALS, PD, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of ALS, PD, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated PACAP.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: November 6, 2018
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona, a body corporate
    Inventors: Robin Polt, Torsten A E Falk
  • Patent number: 10111834
    Abstract: A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and/or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and/or adhesion of the pleura.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: October 30, 2018
    Assignee: TDL Innovations, LLC
    Inventor: Glenn W. Laub
  • Patent number: 10105357
    Abstract: A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of an antibiotic drug or a pharmaceutical acceptable salt thereof. The antibiotic drug is selected from the group consisting of an aminoglycoside antibiotic drug, an anti-fungal antibiotic drug, a Cephalosporin antibiotic drug, a ?-propionamide antibiotic drug, a chloramphenicol antibiotic drug, an erythromycin antibiotic drug, a penicillin antibiotic drug, and a tetracycline antibiotic drug.. The cancer is selected from the group consisting of lung cancer, gastrointestinal tract cancer, colorectal cancer, prostate cancer, bladder cancer, cervical cancer, breast cancer, and blood cancer.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: October 23, 2018
    Assignee: LAUNX BIOMEDICAL CO., LTD.
    Inventors: Chiu-Hung Chen, Show-Mei Chuang, Nai-Wan Hsiao, Ruei-Yue Liang, Xiao-Tong Tan
  • Patent number: 10105381
    Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: October 23, 2018
    Assignee: CMPD Licensing, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 10098920
    Abstract: The invention relates to medicine and chemical and pharmaceutical industry, in particular, to methods for producing a complex of biologically active substances exhibiting hypoglycaemic activity of plant material. A method for producing a complex of biologically active substances exhibiting hypoglycaemic activity comprises extracting bean herb with alcohol followed by concentrating and/or drying the extract, wherein the extraction is carried out with 96% alcohol resulting in a first extract and a bean herb residue, wherein the first extract is concentrated resulting in a first solid extract or it is concentrated and dried resulting in a first dry extract and the bean herb residue is extracted with 70% alcohol resulting in a second extract at least a portion of which being concentrated resulting in a second solid extract or being concentrated and dried resulting in a second dry extract.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: October 16, 2018
    Inventor: Akop Surikovych Kutsanyan
  • Patent number: 10092565
    Abstract: Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminescent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: October 9, 2018
    Assignees: Semorex Technologies Ltd., Ariel-University Research and Development Company Ltd.
    Inventors: Bernard S. Green, Galia Luboshits, Michael A. Firer
  • Patent number: 10092659
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors expressing HER2, wherein the human solid tumor expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2? or 1+ and HER2 FISH negative tumor tissue status.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: October 9, 2018
    Assignees: Synthon Biopharmaceuticals B.V., Yale University
    Inventors: Alessandro Davide Santin, Peter Johannes Goedings
  • Patent number: 10077289
    Abstract: The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: September 18, 2018
    Assignee: Allergan, Inc.
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, Alex J. Thomas, Michael E. Garst
  • Patent number: 10077319
    Abstract: This application provides anti-PCSK9˜GLP-1 fusions and methods for use.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: September 18, 2018
    Assignees: MedImmune, LLC, MedImmune Limited
    Inventors: Anthony Celeste, Matthieu Chodorge, Andrew Buchanan, Cristina Rondinone, Joseph Grimsby, Peter Ravn, Jonathan Seaman, David Fairman
  • Patent number: 10066228
    Abstract: The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: September 4, 2018
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Peter Linsley, Brian James Leppert, Gunnar J. Hanson
  • Patent number: 10053642
    Abstract: There is described a method for producing a biofuel, the method comprising: culturing an Acetobacter lovaniensis bacterium in a growth medium containing phosphate at a level which is more than 1 g/liter, wherein culturing of the bacterium produces the biofuel.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 21, 2018
    Assignee: VERDANT BIOPRODUCTS LIMITED
    Inventor: Irene Finnegan
  • Patent number: 10053521
    Abstract: Naphthalimide compounds as used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bone tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 21, 2018
    Assignee: Alumend, LLC
    Inventors: Ronald E. Utecht, Kaia L. Kloster, Millard M. Judy, Kevin J. Vaska, James L. Matthews
  • Patent number: 10046060
    Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 14, 2018
    Assignee: NoNO INC.
    Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
  • Patent number: 10035847
    Abstract: The invention relates to methods for obtaining antibodies that recognize amyloid protofibrils and antibodies that recognize one or more amyloid protofibrils. Also provided are methods of using the antibodies to prevent or inhibit amyloid disease in a subject, to diagnose amyloid disease in a subject, and to detect amyloid protofibrils in a sample.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: July 31, 2018
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: W. Vallen Graham, Thomas P. Sakmar
  • Patent number: RE47231
    Abstract: The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 12, 2019
    Assignee: PneumRx, Inc.
    Inventors: Glen Gong, Ronald Dieck